Advanced practice providers (APPs) within a preventive cardiology clinic effectively risk stratify and aggressively manage atherosclerotic cardiovascular disease (ASCVD) risk factors, resulting in a reduction in post-intervention, a recent study found. The retrospective study examined data from 595 patients enrolled in a preventive cardiology clinic (PCC) utilizing APPs compared with a propensity-matched cohort (PMC) of 595 patients enrolled in primary care clinical. PCC patents were risk stratified using Framingham risk scoring (FRS) and coronary artery calcium scoring (CACS) and treated based on published guideline-based algorithms. Researchers found:
- CACS was more commonly obtained in PCC patients resulting in reclassification of 30.6% patients to a higher risk category, including statin therapy in 26.6% of low FRS PCC patients with CACS ≥75th MESA percentile.
- Post-intervention mean LDL, non-HDL, and triglycerides were lower in the PCC group.
- Compliance with appropriate lipid treatment was higher in intermediate to high FRS patients in the PCC group.
- Aggressive LDL and non-HDL treatment goals <70 mg/dL and <130 mg/dL, respectively, were more commonly achieved in high FRS PCC patients.
Fentanes E, Vande Hei AG, Holuby S, et al. Treatment in a preventive cardiology clinic utilizing advanced practice providers (APPs) effectively closes atherosclerotic cardiovascular disease (ASCVD) risk management gaps amongst a primary prevention population compared with a propensity-match primary care cohort: A team based care model and its impact on lipid and blood pressure management. [Published online ahead of print April 17, 2018]. Clin Cardiol. doi:10.1002/clc.22963.
This Week's Must Reads
Detection & Management of Resistant Hypertension, Hypertension; ePub 2018 Sep 13; Carey, et al
Does Aspirin Prevent CV Events in Older Adults?, N Engl J Med; ePub 2018 Sep 16; McNeil, et al
Timing of ICD Placement From Last Hospitalization for HF, Circulation; ePub 2018 Sep 13; Ambrosy, et al
FFR and Quality of Life After PCI, Circulation; ePub 2018 Sep 18; Nishi, et al
VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251
Must Reads in Hypercholesterolemia
Racial Differences in Statin Use, JAMA Cardiol; ePub 2018 Jun 13; Nanna, et al
LLT Use in Patients with Elevated LDL-C, Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al
Evolocumab in Differing Patient Populations , J Pharmacokinet Pharmacodyn; ePub 2018 May 7; Kuchimanchi, et al
LDL-C Targets in Elderly Statin Users After ACS, J Am Heart Assoc; ePub 2018 May 12; Alter, et al
Patient Perspectives on Statin Therapy, Clin Cardiol; ePub 2018 May 10; Brinton